Format

Send to

Choose Destination
J Crohns Colitis. 2017 Jan;11(1):3-25. doi: 10.1093/ecco-jcc/jjw168. Epub 2016 Sep 22.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.

Gomollón F1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Dignass A1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Annese V1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Tilg H1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Van Assche G1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Lindsay JO1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Peyrin-Biroulet L1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Cullen GJ1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Daperno M1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Kucharzik T1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Rieder F1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Almer S1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Armuzzi A1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Harbord M1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Langhorst J1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Sans M1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Chowers Y1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Fiorino G1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Juillerat P1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Mantzaris GJ1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Rizzello F1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Vavricka S1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Gionchetti P1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22; ECCO.

Author information

1
Fernando Gomollón, Professor of Medicine, Hospital Clínico Universitario "Lozano Blesa", Universidad de Zaragoza, IIS Aragón, CIBEREHD, Zaragoza, Spain.
2
Axel Dignass, Department of Medicine I, Agaplesion Markus Hospital, Willhelm-Epstein-Straße 4, 60431 Frankfurt/Main, Germany.
3
Vito Annese, Department of Emergency, Division of Gastroenterology, University Hospital Careggi, Largo Giovanni Alessandro Brambilla, 3, 50134 Florence, Italy.
4
Herbert Tilg, Department of Internal Medicine I, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
5
Gert Van Assche, Division of Gastroenterology and Hepatology, University Hospitals Leuven and University of Leuven, 49 Herestraat, 3000 Leuven, Belgium.
6
James O. Lindsay, Department of Gastroenterology, Barts Health NHS Trust, The Royal London Hospital, Whitechapel Road, London E1 1BB, UK.
7
Laurent Peyrin-Biroulet, Department of Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, 54500 Vandoeuvre-Lès-Nancy, France.
8
Garret J. Cullen, Department of Gastroenterology, Centre for Colorectal Disease, St. Vincent's University Hospital, 4 Dublin, Ireland.
9
Marco Daperno, Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, 10128 Torino, Italy.
10
Torsten Kucharzik, Department of Internal Medicine and Gastroenterology, Hospital Lüneburg, Bögelstraße 1, 21339 Lüneburg, Germany.
11
Florian Rieder, Department of Pathobiology/NC22, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195 Cleveland, OH, USA; Department of Gastroenterology, Hepatology and Nutrition/A3, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195 Cleveland, OH, USA.
12
Sven Almer, Department of Medicine, Solna, Karolinska Institute, and, IBD-unit, Center for Digestive Diseases, Karolinska University Hospital, 17176 Stockholm, Sweden.
13
Alessandro Armuzzi, Department of Internal Medicine, IBD Unit Complesso Integrato Columbus, Gemelli Hospital Catholic University Foundation, Via Giuseppe Moscati 31, 00168 Rome, Italy.
14
Marcus Harbord, Imperial College, London; and Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.
15
Jost Langhorst, Department of Internal Medicine and Integrative Gastroenterology, University Duisburg-Essen, Kliniken Essen-Mitte, Am Deimelsberg 34A, 45276 Essen, Germany.
16
Miquel Sans, Department of Digestive Diseases, Centro Médico Teknon, 12 Vilana, 08009 Barcelona, Spain.
17
Yehuda Chowers, Department of Gastroenterology, Rambam Health Care Campus Rappaport Faculty Of Medicine, 8 Ha'Aliya Street, PO Box 9602, 3109601 Haifa, Israel.
18
Gionata Fiorino, IRCCS Humanitas Research Hospital, Department of Gastroenterology, IBD Center, Via Manzoni, 56, 20089 Rozzano, Italy.
19
Pascal Juillerat, Department of Gastroenterology, University Clinic for Visceral Surgery and Medicine, University Hospital Bern Inselspital, Freiburgstrasse 10, 3010 Bern, Switzerland.
20
Gerassimos J. Mantzaris , Department of Gastroenterology, Evangelismos Hospital, 45-47 Ypsilandou Street, 10676 Athens, Greece.
21
Fernando Rizzello, IBD Unit, DIMEC, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy.
22
Paolo Gionchetti, IBD Unit, DIMEC, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy.

Abstract

This paper is the first in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn's disease. Surgical management as well as special situations including management of perianal Crohn's disease of this ECCO Consensus are covered in a subsequent second paper [Gionchetti et al JCC 2016].

KEYWORDS:

Crohn’s disease; Immunosuppressant; biologics; fistulizing disease; perianal disease; steroids; strictureplasty; thiopurine; treatment; vedolizumab

PMID:
27660341
DOI:
10.1093/ecco-jcc/jjw168
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center